Holen Sie sich die Stockscreener-App
1.31
3.68%
-0.05
Vorhandelsmarkt:
1.31
Schlusskurs vom Vortag:
$1.36
Offen:
$1.37
24-Stunden-Volumen:
2.71M
Relative Volume:
2.04
Marktkapitalisierung:
$48.04M
Einnahmen:
$832.00K
Nettoeinkommen (Verlust:
$-135.12M
KGV:
-0.2151
EPS:
-6.09
Netto-Cashflow:
$-124.69M
1W Leistung:
-2.24%
1M Leistung:
-34.50%
6M Leistung:
-29.57%
1J Leistung:
-88.16%
1-Tages-Spanne:
$1.30
$1.38
1-Wochen-Bereich:
$1.30
$1.47
52-Wochen-Spanne:
$1.30
$12.33
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Vergleichen Sie INO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.31 | 68.29M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
INOVIO to Present DNA Medicine Innovations for Rare Diseases at Orphan Drug Summit - MyChesCo
Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug - MSN
INOVIO Announces Pricing of $25 Million Public Offering - Kilgore News Herald
Inovio Pharmaceuticals (INO) Set for Growth With Potential FDA N - GuruFocus
Inovio stock on Piper Sandler's bullish view (INO:NASDAQ) - Seeking Alpha
This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Inovio Pharmaceuticals at Overweight With $5 Price Target - MarketScreener
Inovio (INO) Gains Favorable Analyst Rating with $5 Price Target - GuruFocus
Inovio Pharmaceuticals Announces Public Offering Agreement - The Globe and Mail
INOVIO Pharmaceuticals: Pioneering Rare Disease Therapies with DNA-Encoded Antibodies - AInvest
INOVIO to Present at Upcoming Scientific Conference - StreetInsider
INOVIO to Present at Upcoming Scientific Conference | INO Stock News - GuruFocus
INOVIO's Revolutionary DNA Medicine Technology Takes Center Stage at Major Rare Disease Conference - Stock Titan
INOVIO Announces Public Offering of Common Stock and Warrants - MyChesCo
Inovio Pharmaceuticals announces proposed public offering of common stock and warrants - MSN
Inovio Pharmaceuticals Plunges 29.44% on $25M Offering - AInvest
Inovio Stock’s Unexpected Dive - StocksToTrade
INOVIO Announces Pricing of $25 Million Public Offering | INO Stock News - GuruFocus
Inovio prices $25 million public offering of common stock and warrants - Investing.com
Inovio prices $25 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals stock plunges after announcing public offering By Investing.com - Investing.com India
INOVIO announces proposed public offering of common stock By Investing.com - Investing.com South Africa
INOVIO Pharma Announces Proposed Public Offering - Nasdaq
Inovio Pharmaceuticals (INO) Announces Public Offering Plan - GuruFocus
Inovio Pharma dives on equity offering plans - TradingView
Inovio Pharmaceuticals stock plunges after announcing public offering - Investing.com
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from Russell Small Cap Completeness Index - MarketScreener
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) dropped from Russell 3000 Value Index - MarketScreener
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides
Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World
Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio shareholders approve board nominees and proposals - Investing.com Australia
Inovio Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight - The Globe and Mail
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines - MyChesCo
Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst - Defense World
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Inovio Pharmaceuticals (INO) Sees Price Target Adjustment by Opp - GuruFocus
Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN
Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus
Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus
Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):